References: Hair growth and hair loss
Gan To Kagaku Ryoho. 1990 Sep;17(9):1909-15.
[Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers]
[Article in Japanese]
Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A, et al.
Dept. of Urology, Kobe University School of Medicine.
Fifteen patients with advanced transitional cell carcinoma of the urothelial tract were treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) chemotherapy. Eleven patients were treated to metastatic lesions after surgical resection of primary cancers. One out of 15 patients died of chemotherapy. Of the remaining 14 patients, CR was achieved in one and PR was achieved in seven, clinically. The response rate was 57.1% and the median response duration was 12.6 months. In the patients who had been resected their primary lesions, the response rate was 70% and the duration was 14.1 months. Six patients, including five PRs and one NC, underwent surgical resection and re-staging of the residual tumors after chemotherapy. Clinical response coincided with pathological one in all 6 cases. Three patients were observed the decrease of the lung metastasis, which rate was more than 90%. Two out of 3 who did not show any invasion into the lymph channels in the resected residual tumors, have been free of a recurrence through-out the course of at 47 or at 42 months. However, another patient with lymph channel invasion died of metastasis of the mediastinal and paraaortic lymph nodes. Regarding the frequency of side effects, it seemed to be no significant difference between full and 80% doses administration. In the effectual cases, the residual tumors should be resected surgically and re-staged pathologically.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2393308&dopt=Abstract
Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1994 Jan;10(1):38-9.
[Cross transposition of expanded scalp flaps for the treatment of postburn cicatricial alopecia]
[Article in Chinese]
Long J, Ma E, Liu F.
Department of Burns and Plastic Surgery, First Affiliated Hospital of Hunan Medical University.
When the area of alopecia is very large, the normal scalp is not sufficient to cover the defect resulting from excision of the alopecia. From August 1987 to December 1989, 8 cases with large defect of scalp are repaired by means of expanded cross scalp flaps with good result. Among 8 cases, 7 are male and 1 female, and the largest area of alopecia is 300 cm2 and the smallest 112 cm2, with a mean of 191 cm2. Two expanders are buried under the galea aponeurotica on both sides of alopecia, and the scalp is expanded. The central part of the expanded scalp is chosen to form the "major flap", the lateral part of the expanded scalp to form the "adjuvant flap". Two flaps are then crossed and the defect is repaired. The method of scalp expansion and "axial flap" is used in marginal alopecia. An expander is buried under the galea aponeurotica on each side of the alopecia. After the scalp is expanded, the central part of the expanded scalp is chosen to from "axial flap" with the pedicle consisting of superficial temporal artery or occipital artery and the lateral part of the expanded scalp to form the "adjuvant flap". Then two flaps are transposed and the defect is thus repaired.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8087689&dopt=Abstract
Lipitor
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Hair loss research references ||
E-Mail Us